biostudies-literatureTao YChief Scientist Office601https://www.ebi.ac.uk/biostudies/studies/S-EPMC11852610biostudies-literatureUnknown17(4)<b>Background:</b> Better prognostic biomarkers are needed in older adults with cancer. There are established links between N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) and sarcopenia, and sarcopenia is associated with poorer cancer survival. However, there are limited data regarding baseline NT-proBNP as a biomarker of cancer outcome. The GO2 trial recruited older and/or frail United Kingdom (UK) patients with advanced gastroesophageal cancer and investigated the role of chemotherapy dose de-escalation. Using the GO2 database, we sought to investigate the prognostic role of NT-proBNP as well as the interaction between NT-proBNP and frailty. <b>Methods:</b> This was a post-hoc analysis of a completed clinical trial. Frailty measures included ECOG performance status (PS) and GO2 frCancersN-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP)-A Prognostic Biomarker in Older and/or Frail Adults with Advanced Gastroesophageal Cancer: A Post Hoc Analysis of the GO2 Clinical Trial.PMC11852610CAF20/01Hall PSPetty RDBaxter MATao YLang CCfalseN-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP)-A Prognostic Biomarker in Older and/or Frail Adults with Advanced Gastroesophageal Cancer: A Post Hoc Analysis of the GO2 Clinical Trial.<b>Background:</b> Better prognostic biomarkers are needed in older adults with cancer. There are established links between N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) and sarcopenia, and sarcopenia is associated with poorer cancer survival. However, there are limited data regarding baseline NT-proBNP as a biomarker of cancer outcome. The GO2 trial recruited older and/or frail United Kingdom (UK) patients with advanced gastroesophageal cancer and investigated the role of chemotherapy dose de-escalation. Using the GO2 database, we sought to investigate the prognostic role of NT-proBNP as well as the interaction between NT-proBNP and frailty. <b>Methods:</b> This was a post-hoc analysis of a completed clinical trial. Frailty measures included ECOG performance status (PS) and GO2 fr2025-01-01T00:00:00Z2025 Feb2025-04-22T20:06:32.373Z2025-04-06T03:03:55.63ZS-EPMC118526104000219610.3390/cancers17040601